ESMO 2023

Remarkable efficacies in patients with HER2+ mBC with…

My highlights of ESMO23 in metastatic breast cancer

Preoperative checkpointinihition in ER+ disease

5 year follow-up

Highlights in eBC

New 3rd line therapy for RCC

When the history of ADC is written: Redefining…

Clearing up non-clear cell RCC

The FGFR story in bladder cancer at ESMO23

Lu-PSMA leads forward

My highlights from ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Tarlatamab in SCLC

Amivantamab as a new SoC for EGFR Exon 20…

ALINA - immediate change of practice!

Data updates for CDK4/6 inhibitors in EBC at ESMO23 -…

What was the most exciting news at ESMO23?

New and better biomarkers are needed!

What is your definition of triple-negative breast…

Use of immunotherapy in the perioperative setting of…

Highlights in eBC

My highlights of ESMO23 in early breast cancer

Negative EFS results from NeoTrip

ER-low corresponds diagnostically to ER-0 breast cancer

Clinically relevant effect of pembro also in PCR

Carry-over effects in monarchE confirmed

Ribociclib effective in all subtypes

Pembrolizumab solidifies as SOC in early-stage TNBC

Consolidation of data in early HR+ and triple-negative…

Metabolomics reveal differential expression of OMEGA 3…

Our guidelines are correct

HR+ study with > 20 % PCR

Detailed view of nodal-negative patients

Neoadjuvant IO - is their new strategy in HR+ breast…

Preoperative checkpointinihition in ER+ disease

Prognostic score in early HR+/HER2-BC: translational…

MonarchE - trial update

New data on neoadjuvant immunotherapy

5 year follow-up

Analysis of tumour microenvironment and…

La Metabolomica svela l’importanza di OMEGA 3 & OMEGA 6…

Punti salienti in eBC

Studio NeoTrip: negativi i risultati

Nouvelles données sur l'immunothérapie néoadjuvante

New ADC for metastatic breast cancer?

What was the most exciting news at ESMO23?

New targets, new linker, new ADCs - much more to learn…

How to organize a molecular tumorboards in breast…

Improvement of therapy outcome by app-based patient…

ADC + Immunotherapy - the BEGONIA study paradigm

Even more new generation ADCs in breast cancer?

Remarkable efficacies in patients with HER2+ mBC with…

My highlights of ESMO23 in metastatic breast cancer

DATO-DX - where is it going?

Our guidelines are correct

New ADC in HR+ disease

Improved oncological therapy with the smartphone

Can surgery be spared following primary systemic…

TULIP: Trastuzumab duocarmazine without OS benefit

TROP2 expression as a potential mechanism of resistance…

Fulvestran better than anastrozole, but no survival…

T-DXd in HER2+ patients with brain metastases

Dato-DXd - new player in advanced luminal disease

Abemaciclib remains consistent in 5-year follow-up

Benefit for SG even after intensive pretreatment

Still on track for success in HER2-low MBC

Duvalumab + Dato-DXd effective

Highlights in mBC

Robust data from the monarchE

OP-1250 (Palezestrant) confirms the role of SIRDs after…

HS20089 - a novel ADC is coming for TNBC

Patient-centered molecular medicine - a new approach

HER2DX in the PHERgain trial

OP seems to be dispensable for super responders

T-DXd - new standard of care for brain mets?

HER2DX en el estudio PHERgain

Lo studio BEGONIA nelle paziento con tumore triplo…

Punti salienti in mBC

HS20089 - un nuovo ADC che si affaccia sulla scenda del…

ADC + Immunothérapie: L'exemple de l'étude BEGONIA par…

T-DXd - nowy standard postępowania w przerzutach do…

Czy możliwa jest rezygnacja z chirurgii po indukcyjnym…

OP-1250 (Palezestrant) ulteriore conferma del ruolo dei…

La expresión de TROP2 como potencial mecanismo de…

Should we use zoledronic acid in all ADT patients?

The optimal timing of RT after radical prostatectomy…

Targeted therapy will move forward - but more robust…

Brave New World in mCRPC

Embark without fear

IO therapy in metastatic prostate cancer.

EMBARK expands ENZA indication to PCa

PSMAfore unleashes urooncologic opportunity

Lu-PSMA leads forward

Early use of enzalutamide in advanced prostate cancer

EMBARK - Quality of Life

ENZA P:Trial and controversies

TITAN: ultra-low PSA = best prognosis

Longterm toxicity of adjuvant RT after prostatectomy

When immunotherapy is probably not the best choice: The…

RADICALS RT: Trial and controversies

CXCR2 inhibitor in PCa

Immunotherapy in metastatic PCa

Salvage radiotherapy the new standard

STAMPEDE. Bone prediction not for everyone - better…

Osteoprotection at mHSPC

Combination of radioligand therapy with chemotherapy…

Big data and AI prediction tools

Negative data for pembrolizumab in mHSCPC & mCRPC

Precision medicine at mCRCP

STAMPEDE data. Skelettstärkande och riskstratifiering.

CXCR2 hämmare och prostatacancer

Immunterapi vid prostatacancer

Big Data och AI för prediktion vid prostatacancer

EMBARK och livskvalitet

FGFR inhibitors and ADC combinations in urothelial…

Part1: New standard of care in first line urothelial…

Amazing new data in bladder cancer

Unique bladder delivery system of gemcitabine herolds…

The FGFR story in bladder cancer at ESMO23

Chemo-IO establishes itself in the first-line treatment…

DAD, DAD-IO

FGFR inhibitors: What is the best scenario for this…

EV + Pembro as standard of care in first-line therapy…

When the history of ADC is written: Redefining…

L'histoire du FGFR dans le cancer de la vessie à…

Inhibidores de FGFR: Cual es el mejor escenario para…

Reescribiendo la historia de una enfermedad: Nuevo…

Is de-escalating therapy ready for prime-time?

Where does the future therapy go in renal cell…

Clearing up non-clear cell RCC

Belzutifan in later lines of therapy

New mode of action in mRCC - ready for prime time?

Kidney cancer highlights at ESMO23

New 3rd line therapy for RCC

Intermittent therapy also possible with TKIs

Moving patients to the neoadjuvant setting in…

Adjuvant alectinib in patients with early-stage ALK+…

Scene is set for inductive immunotherapy

Perioperativ immunotherapy for all resectable stage…

My highlights from ESMO 2023

ALINA - immediate change of practice!

Circulating DNA in AEGEAN trial

Substantial improvement in local regional NSCLC

ALINA - a new paradigm in operated NSCLC with…

Neoadjuvant chemo-immunotherapy new standards in early…

Perioperative IO: OS-benefi from KEYNOTE-671

ALINA - un nouveau paradigme dans cBNPC avec la fusion…

I miei punti salienti di ESMO 2023

Les points forts de l'ESMO 2023

Gros progrès dans les traitments medicaeux des stades…

ESMO2023-impact on everyday practice!

Rare oncogenic alterations: landmark results on exon 20…

Activating EGFR-mutation - what's coming up?

RET-TKI: Standard in 1st line RET fusion-positive NSCLC

New standard of care for metastatic EGFR exon 20…

MARIPOSA: Trial and controversies

Changing treatment landscape in EGFR-mutated NSCLC

My highlights from ESMO 2023

Practice changing results on exon 20 insertion mNSCLC

Amivantamab upfront? MARIPOSA trial

Adagrasib + pembrolizumab in patients with KRASG12C…

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

By unanimous decision and still the champion –…

Amivantamab at progression? MARIPOSA-2 trial

Does immunotherapy still have a place in EGFR-positive…

Big improvements in early stage and a subset of…

Substantial improvement in rare alterations

LIBRETO - a positive study, but was it necessary?

NRG fusions: a new drugable target?

Amivantamab as a new SoC for EGFR Exon 20…

Brain metastases – options to improve the systemic…

Do ADCs have brain activity?

Treatment sequences for EGFR-mutated Patients

MARIPOSA II: Trial and controversies

PAPILLON - bringing together therapy for the 1st line

I miei punti salienti di ESMO 2023

Datopotamab deruxtecan - new SOC in 2nd line adv/met…

Heeft immunotherapie nog een plek in de behandeling van…

Amivantamab at progression? MARIPOSA-2 trial

Quelles séquences thérapeutiques pour les patients EGFR…

Gros progrès dans les traitments medicaeux des stades…

Veränderte Behandlungslandschaft bei EGFR-mutiertem…

Nieuwe standaard voor gemetastaseerd EGFR exon20…

Amivantamab upfront? MARIPOSA trial

Les points forts de l'ESMO 2023

Tarlatamab in SCLC

A new option in relapsed SCLC

Evolution of the revolution - the RUBY trial

New data on sarkomas

New data on H&N Cancer

First data on luveltamab in multiline treatment for…

Precision oncology in CUP

PCO Therapeutics